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INTRODUCTION  
Ingestible Electronically Controlled Drug Capsule is the 
targeted delivery of drug in the Gut. It cons ists of an ingestible 
capsule consist ing of a pH sensor which release drug in a 
particular pH, thermosensors which monitor temperature of 
body, battery which provide cont inuous  power supply to the 
capsule, F luid Pump, Drug Reservoir and Dispens ing hole. By 
the help of gut pH, pressure and t emp erature a wireless mot ility 
capsule has been est ablished. It has been constructed to be 
engulfed and didn’t int erfere the nat ural human digestive 
system1 .  The scheme comprises of a digestible ant enna and 
microchip to a normal-s ize shell. When we ingest the pill then it  
starting working by producing the s ignals which is receiving by 
a small electronic device supported by the patient. This device 
is linked with laptop, cell phone or computer, ale rting doctors  
and family member2 .  
Advantages of e-Capsule:  
It has potentials to be a valuable research tool for the 
develop ment of any new drug that is  deliver ed through int estinal 
tract. With help of this device the locat ion in the gut can b e 
det ermined with good accuracy 3. It has been developed to 
measure trans it time4 . It will help effort lessly to attain dat a on 
the intest inal absorption of a drug in humans. It will help to 
communicate t he patient  with the Physician and the Pharmacist  
through mobile or laptop. It is used to locally treat a medical 
condition.  
Problem State ment  
The problem with administ ering numerous medications orally is  
that a pill oft en will not dissolve at precisely the right site in the 
gastrointest inal tract where the medicine can be absorbed into 
the bloodstream5  
LITERATURE REVIEW 
 Physical delive ry of Pharmaceutical  agent:  
Zdeblick Mark and his  co-worker have developed Composit ions, 
systems and met hods  that suggested the ident ification of the 
act ual physical delivery of a pharmaceut ical agent to a body. It  
includes an ident ifier and an active agent. The innovator finds  
use in a variety of different applications such as monitoring of 
therapeutic regimen compliance and tracking the history of 
pharmaceut ical agent6.  
 Analyte  monitoring and drug deli very system:  
Holmes Elizabet h and his co-worker have work on the analyte 
monitoring and drug delivery system. The innovat ion narrates to 
an ingestible, implantable or wearable medical device cons isting 
of a microarray which encompasses a bioact ive agent able of 
int eract ing with a disease marker biological analyte. Mechanism 
includes a reservoir that cont ains with minimum one therap eutic 
mediator and has the capacity of releas ing the t herap eutic 
mediator from the medical gadgets  and numerous microchips 
consist ing of a microarray scanning instrument that have the 
ability of analysing the physical paramet er data of a 
communication between the disease marker biological analyte 
with the bioactive agent. It also contains a biometric recognition 
device proficient of linking t he physical paramet er dat a with an 
analyte int eract ion profile; an out er surface gadget capable of 
helping int eract ion between the biometric recognition device, 
microarray scanning device, and t he therapeutic agent ; and a 
power source to control the medical gadgets 7.   
 Re mote  Controlled Capsule:  
Remot e Controlled Capsule (RCC) is a new t echnique to 
underst and non-invas ive drug delivery to the specific locations  
of human gut. Human Drug Absorption (HDA) studies are t aken 
effort lessly to attain data on the int estinal absorption of a drug 
in humans. This system has been prearranged using MEMS 
technology to make available for the delivery of an ext ens ive 
choice of different drug formulations . A magnetic Marker 
Monitoring (MMM) system was est ablished to monit or t he place 
of the capsule inside the gut. A new method to indicate the drug 
release, called as  Indicat ing System built on Abrupt Movement  
of Marker (ISAMM), was proposed in this study.  It has been 
proved by animal models8 .  
 
Figure 1: Novel Micro-Fabricat ed Thruster For Drug Release In 
Remot e Controlled Capsule 
ABSTRACT 
The Ingestible Electronically Controlled Drug-delivery System consists of electronically design capsule that navigates the 
digestive system by assessing human pH levels, which it reads through pH sensors. When the pH sensors identify a 
specified pH level that indicates arrival at the destination, the e-Capsule begins dispensing medication which it can do all 
immediately, in a sustained released, extended release or controlled release form. When it is activated, they send messages 
to a detector located on the patient's body that can send e-mails or text messages to doctors or Pharmacist notifying them 
the effect of medication that has been taken and they altered the medication accordingly if needed. Researchers are hopeful 
that this technology will improve medication observance, targeted drug delivery and drug of choice.  
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Magnetic marke r monitoring:  
A patent ed remote contro lled capsule (RCC) has newly been 
des ign to provide noninvas ive drug delivery to cert ain sit es in 
the human gut that allows assessment of local gastroint estinal  
(GI) drug absorption under a normal physiological environment. 
For this purpose rate and ext ent  of aminophylline absorption 
aft er s ite-sp ecific delivery of the drug in the GI tract has been 
studied using RCC and a magnetic marker monitoring (MMM) 
technique. After this study it was found that the propriet ary of 
the RCC and MMM technique offer the chance to gain dat a on 
the intestinal absorption of a drug in humans under noninvas ive 
conditions. Aminophylline is quickly and well absorbed from 
the small bowel. While colonic absorption was restricted by the 
poor water condit ion alt hough effective absorption was  
observed from the ascending colon. This offers a chance for 
rat ional development of modified-release formulations  as  well 
as alternative dosage forms9 .  
Intelligent Pill:  
After the approval of the first camera pill by Federal Drug 
Administration in 2001 for diagnost ic purposes, many 
researchers are then working to des ign such pill that also have 
the capability to deliver the drug. Aft er seven years the efforts  
succeed and a renowned organizat ion has  developed an 
int elligent pill which can be electronically programmed to 
control the drug delivery to a pre-defined rat e in the Gut. It can 
be monitor eas ily and also ident ified its location by attaching 
different sensors such as t emperature sensor and pH sensors  
which is used to track the drug and also aid when to release the 
drug in the Gut.   The iP ill discharges medicine from its drug 
reservoir through microprocessor scaled pump, letting accurate 
programmable drug delivery. It also have the ability to measure 
the t emp erature and pH10.  
 .  
Figure 2 : iPill  
Magnetic Pill System:  
Brown Univers ity researchers are working with the problem that  
orally administ ered drug will never dissolved at appropriate s ite 
in the Gut. They succeeded to solve this problem by developing 
a new magnet ic p ill system. T his has opened a big horiz on in 
the field of research. The system comprises of gelatin capsules  
along with a t iny magnet and an ext ernal magnet t hat can 
precisely sense the force between them. The pill deviat e that  
force where needed to grip the pill in place. The ext erior 
magnets can intellect the pill's pos ition. To avoid any injury to 
nearby tissue we have to monit or the force that are applying 
through external magnet . To avoid this Bryan Laulicht took 
careful dimensions  and made an ext ernal magnet structure with 
sens itive computer regulator and feedback mechanisms11 .  
 
Ingesti ble e vent marker (IEM) system:  
An Ingest ible event marker (IEM) system is des ign by an 
organiz ation that covers a personal s ignal receiver and an 
ingest ible event marker. It is act ivated   upon cont act with a 
target int erior physiological s ite of a body like digestive tract  
int ernal target s ite. The personal s ignal receiver is aimed to be 
related with a physiological location such as ins ide of or on the 
body and to receive a s ignal through IEM. The IEM 
programmes a s ignal which is received by the personal s ignal 
receiver12. An ingestible therapy activator system and method 
are one aspect of the ingestible therapy act ivator t hat includes  
an ingestible device having an effector module to send an 
effector inst ruction and a responder module relat ed with a 
therapeutic device. The responder module may receive and 
process the effector instruct ion, result ing in a response by the 
therapeutic device such as  therapeut ic device includ e act ivating 
a therapy, deact ivat ing a therapy, modulat ing a therapy, and 
discontinuing a therapy13. Ingest ible event markers having high 
reliability are provided. Asp ects of the ingest ible event markers  
comprise a support, a control circuit, a first elect rochemical 
mat erial, a second electrochemical material and a membrane. In 
addit ion, the ingest ible event markers might comprise one or 
more components that impart  high reliability to the ingestible 
event marker. Furt her, the ingestible event markers may co ntain 
an act ive agent. In some asp ects , the active agent, such as a 
pharmaceut ically active agent or a diagnostic agent may be 
associat ed with the membrane14.  
A Miniaturize d Ele ctroni c De vi ce:  
A miniaturized in-body electronic device is provided containing 
one or more ant ennas may be galvanically joined to receive an 
alt ernat ing current (AC) s ignal through the body of a subject  
where the in-body electronic device is located. Power extraction 
circuitry is configured to ext ract electrical power from the AC 
signal received by the ant enna. The extracted electrical power is  
used for electrically powering one or more components of the 
electronic device. A transmitter is coup led to receive power 
from the power ext ract ion circuitry. A controller is coupled to 
the transmitter. The controller is  configured to activate the 
transmitter to generat e a sequence of intermittent transmission 
bursts for transmitting an uplink signal; a t ransmiss ion burst  
may have a higher instant aneous power level than an 
inst ant aneous power level of the AC signal received by the 
ant enna15.  
Teppe r Robert and his co-workers:  
Tepper Robert and his co-workers describe a devices, systems, 
and kits for delivering subst ances  to t issues . The devices  usually 
include one or more chambers  and a reservoir within each 
chamber. The reservoir may locally deliver a micro dose amount  
of a substance to a target tissue. In some variat ions, a micro 
dose amount is used in early human studies , e.g., before a phase 
I clinical trial, to evaluat e the effect of the subst ance on a target  
tissue, or to obt ain pharmacokinetic or met abolic dat a. In other 
variations , a micro dose quantity is used to locally treat a 
medical condition. In yet other variat ions , a micro dose amount  
is used t o locally deliver a cont rast agent for a struct ural or 
functional imaging procedure. Methods for delivering and 
retrieving the devices  from the t arget t issue are also descr ibed16 .  
Ele ctroni c Control of Drug Deli very System:  
Saad David and his  co-worker explain a drug delivery device for 
driving an electrotransport current through a body surface of a 
user is provided. The device cont ains a p atch with two 
electrodes and one or more reservoirs storing a t herap eutic 
agent. The one or more reservoirs release the therapeut ic agent  
into the body surface of the user when the reservoirs are locat ed 
over the electrodes t o creat e an electrical path for the 
electrot ransport current. The device consists of a controller   
which regulates a controllable power supply to drive the 
electrot ransport current t hrough the body surface of the user in a 
programmed profile17 .  
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Figure 3: External Core of Capsule 
 
 
Figure 4: External Core of Capsule 
 
 
Figure 5: Internal Core of Capsule 
 
 
Figure 6: Labelling of Capsule 
DISCUSSION 
Electronically drug delivery system will bring new horiz on in 
the t arget  drug delivery system. It is beneficial to monitor the 
drug delivery in t he Gut and also helps to improve the 
therapeutically drug regimen. If the capsule is  introduced in the 
blood t hrough microencapsulation then it will helps in the 
Physician and Pharmacist to monit or the drug throughout the 
body compartment and it is used as research tools for clinical 
trials . The purposed structure for the electronically controlled 
drug capsule is as  follows  
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